Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

(2018) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor

(2017) Sean Caenepeel et al.   Oncotarget

Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM

(2016) Leona Rohrbeck et al.   CELL DEATH AND DIFFERENTIATION

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

(2016) Iñigo Landa et al.   JOURNAL OF CLINICAL INVESTIGATION

BRAF Inhibition inBRAFV600E-Positive Anaplastic Thyroid Carcinoma

(2016) Annette M. Lim et al.   Journal of the National Comprehensive Cancer Network

Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies

(2016) Johan van Griensven et al.   NEW ENGLAND JOURNAL OF MEDICINE

FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing

(2016) Ronglai Shen et al.   NUCLEIC ACIDS RESEARCH

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer

(2016) F. Pietrantonio et al.   Cancer Discovery

Use of vemurafenib in anaplastic thyroid carcinoma: a case report

(2015) Kristen A Marten et al.   CANCER BIOLOGY & THERAPY

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

(2015) Douglas B. Johnson et al.   EUROPEAN JOURNAL OF CANCER

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing

(2015) John W. Kunstman et al.   HUMAN MOLECULAR GENETICS

BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

(2015) Inna V. Fedorenko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

(2015) Hyung Kwon Byeon et al.   MOLECULAR CARCINOGENESIS

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF Inhibitor Dabrafenib in Patients with MetastaticBRAF-Mutant Thyroid Cancer

(2015) Gerald S. Falchook et al.   THYROID

Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032

(2015) Elisabetta Vergani et al.   NEOPLASIA

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

(2014) Nishant Agrawal et al.   CELL

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

(2014) C. M. Lovly et al.   CLINICAL CANCER RESEARCH

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer

(2014) D. G. McFadden et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway

(2014) Matthias Drosten et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

(2013) Nobuya Ishii et al.   CANCER RESEARCH

BRAF V600E Inhibition in Anaplastic Thyroid Cancer

(2013) Michael H. Rosove et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression

(2013) Mabel Ryder et al.   PLoS One

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas

(2013) Cristina Montero-Conde et al.   Cancer Discovery

An Optimized microRNA Backbone for Effective Single-Copy RNAi

(2013) Christof Fellmann et al.   Cell Reports

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic

(2012) G Tomás et al.   ONCOGENE

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

(2011) Debyani Chakravarty et al.   JOURNAL OF CLINICAL INVESTIGATION

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Tumor-Associated Macrophages (TAMs) Form an Interconnected Cellular Supportive Network in Anaplastic Thyroid Carcinoma

(2011) Bernard Caillou et al.   PLoS One

Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

(2011) P. S. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice

(2011) A. T. Franco et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy

(2010) Robert L. Foote et al.   THYROID

Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1

(2009) J. C. Ricarte-Filho et al.   CANCER RESEARCH

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential Effects of Interleukin-2 and Interleukin-15 versus Interleukin-21 on CD4+ Cutaneous T-Cell Lymphoma Cells

(2008) M. Marzec et al.   CANCER RESEARCH

Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer

(2008) M. Ryder et al.   ENDOCRINE-RELATED CANCER

Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced byMycand mutantKras

(2008) Katrina Podsypanina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA